{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-120772","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.236431+00:00","generated_at":"2026-05-21T04:46:20.677571+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Forte Biosciences Q1 net loss $1.37/share; FB102 celiac data expected, vitiligo trial dosed","bullets":["Net loss per share ($1.37) vs ($4.03) YoY; net loss $15.7M on R&D spend of $12.7M.","Cash $45.9M at March 31, 2025, up from $22.2M at year-end 2024.","FB102 celiac disease topline data planned for Q2 2025; first vitiligo patient dosed.","R&D expenses $12.7M (+188% YoY) driven by manufacturing and clinical trial costs.","Shares outstanding 6.6M plus 4.8M pre-funded warrants as of March 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-120772","json":"https://secwatch.observer/filing/0001193125-25-120772.json","markdown":"https://secwatch.observer/filing/0001193125-25-120772.md","text":"https://secwatch.observer/filing/0001193125-25-120772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525120772/0001193125-25-120772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525120772/d818687d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:46:20.677571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}